Bayer operationally strong - strategic focus on Life Science businesses
- Details
- Category: Bayer
Sales of the Bayer Group rose by 5.6 percent in the third quarter of 2014 to EUR 10,187 million (Q3 2013: EUR 9,643 million). Adjusted for currency and portfolio effects (Fx & portfolio adj.), sales grew by 7.4 percent. EBIT rose by 12.7 percent to EUR 1,376 million (Q3 2013: EUR 1,221 million).
AstraZeneca launches Healthy Heart Africa programme to address hypertension in Africa
- Details
- Category: AstraZeneca
AstraZeneca has launched a programme aimed at tackling the burden of hypertension in Africa. Healthy Heart Africa is designed in consultation and collaboration with non-governmental and community based organisations, international organisations, health experts and governments to support local health systems by increasing awareness of the symptoms and risks of hypertension and offering education, screening, treatment and control.
Bristol-Myers Squibb enters into agreement that provides an exclusive option to acquire F-star Alpha Ltd. and its novel HER2-targeted therapy
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and F-star Alpha Ltd. have entered into an agreement that provides Bristol-Myers Squibb the exclusive option to acquire F-star Alpha Ltd, and gain worldwide rights to its lead asset FS102.
AstraZeneca strengthens partnership with the University of Cambridge
- Details
- Category: AstraZeneca
AstraZeneca, together with its global biologics research and development arm, MedImmune, has entered into four new collaborations with the University of Cambridge, building further on their existing partnership.
Roche delivers solid sales growth for the first nine months of 2014
- Details
- Category: Roche
Group sales were 34.8 billion Swiss francs, 5% higher at constant exchange rates and stable in Swiss francs for the nine months ended 30 September 2014. A number of currencies remained weaker against the Swiss franc throughout the year, most notably the US dollar, as well as all Latin American currencies and the Japanese yen.
Novo Nordisk second best science employer in the world
- Details
- Category: Novo Nordisk
Novo Nordisk ranked second in the 2014 Science Careers Top Employers Survey, which is a big jump up the list from last year's ranking where Novo Nordisk came in at number 11. The key drivers of the ranking were the categories 'Treats employees with respect', 'Has loyal employees' and 'Is socially responsible'.
Bayer supports World Thrombosis Day as founding global partner
- Details
- Category: Bayer
As founding global partner, Bayer HealthCare joins the International Society on Thrombosis and Haemostasis (ISTH) today to launch the annual World Thrombosis Day. Held for the first time, World Thrombosis Day is dedicated to focusing attention on the underlying condition responsible for the three leading causes of cardiovascular death - heart attack, stroke and venous thromboembolism (VTE, or venous blood clots).
More Pharma News ...
- Positive results from Phase IIb benralizumab study in severe asthma
- New data on the global economic impact and burden of preventable blindness and vision impairment
- GSK commits further funding to advance bioelectronics research with creation of $5 million Innovation Challenge Fund
- Novartis announces clinical collaboration to evaluate Bristol-Myers Squibb's novel immunotherapy in combination treatments for NSCLC
- Bayer closes acquisition of consumer care business of Merck & Co., Inc., United States, for USD 14.2 billion
- Pfizer and Kyowa Hakko Kirin to collaborate on immuno-oncology combination study
- Novo Nordisk establishes new obesity research unit in Seattle